Effectiveness of Anthelmintics: Specific Recommendations for Products Proposed for the Prevention of Heartworm Disease in Dogs

Guidance for Industry

Submit comments on this guidance at any time. Submit electronic comments to https://www.regulations.gov. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number FDA-2022-D-2899.

For further information regarding this document, contact AskCVM@fda.hhs.gov.

Additional copies of this guidance document may be requested from the Policy and Regulations Staff (HFV-6), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Place, Rockville MD 20855, and may be viewed on the Internet at https://www.fda.gov/animal-veterinary, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or http://www.regulations.gov.
Table of Contents

I. Introduction .......................................................................................................................... 1

II. Recommended Approach to Demonstrate Substantial Evidence of Effectiveness ......... 1

III. Laboratory Dose Confirmation Studies ............................................................................. 2
    A. Number of Studies .......................................................................................................... 2
    B. *D. immitis* Isolates ...................................................................................................... 3
    C. Number of Dogs per Investigational Group ............................................................... 3
    D. Number of L3 Injected for Induced Infection ............................................................. 3
    E. Pre-existing Heartworm Infection ............................................................................... 3
    F. Assessment of Effectiveness ....................................................................................... 3
       1. Parasite Counts ........................................................................................................ 3
       2. Criteria to Demonstrate Effectiveness .................................................................. 4
    G. Pharmacokinetic Evaluation ....................................................................................... 4

IV. Field Effectiveness Study .................................................................................................. 4
    A. Study Duration ............................................................................................................ 5
    B. Enrollment .................................................................................................................. 5
    C. Location of Study Sites ............................................................................................. 6
    D. Assessment of Effectiveness ....................................................................................... 6
    E. Active Control Group ................................................................................................. 6
    F. Number of Evaluatable Cases .................................................................................... 7
    G. Pharmacokinetic Evaluation ....................................................................................... 7
Effectiveness of Anthelmintics: Specific Recommendations for Products Proposed for the Prevention of Heartworm Disease in Dogs

Guidance for Industry

I. Introduction

This guidance provides recommendations for the evaluation of effectiveness for drugs indicated for the prevention of heartworm disease caused by *Dirofilaria immitis* in dogs. These recommendations should be read in conjunction with Guidance for Industry (GFI) #90 (VICH GL7), “Effectiveness of Anthelmintics: General Requirements,”¹ and GFI #111 (VICH GL19), “Effectiveness of Anthelmintics: Specific Recommendations for Canines,”² and are intended to provide additional detail to elements of study design and interpretation under the recommendations laid out in these guidances.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

The recommendations in this document are based on current technology and veterinary epidemiology, including available diagnostic methodologies. Individuals pursuing approval of drugs indicated for the prevention of heartworm disease in dogs are encouraged to discuss deviations from these recommendations with FDA, especially as advances in veterinary medicine related to heartworm disease, including disease epidemiology, isolate characterization, or diagnostic testing are identified.

II. Recommended Approach to Demonstrate Substantial Evidence of Effectiveness

The recommended approach to demonstrate substantial evidence of effectiveness of an investigational new animal drug intended for the prevention of heartworm disease in dogs is for

¹ [https://www.fda.gov/media/70349/download](https://www.fda.gov/media/70349/download) (August 2022). When final, this guidance will represent FDA’s current thinking on this topic.

² [https://www.fda.gov/media/70091/download](https://www.fda.gov/media/70091/download) (August 2022). When final, this guidance will represent FDA’s current thinking on this topic.
the sponsor to conduct two laboratory dose confirmation studies and one multi-site field
effectiveness study in accordance with the principles of Good Clinical Practice (GCP) as
described in GFI #85 (VICH GL9), “Good Clinical Practice.” Laboratory dose confirmation
studies are experimentally-induced infection studies that provide known exposure to infectious
*Dirofilaria immitis* (*D. immitis*) larvae (L3) due to contemporaneous experimental infection of
the same number of L3 to negative control dogs and dogs administered the investigational new
animal drug. Laboratory dose confirmation studies also allow for quantitative evaluation of
outcome by determining the presence of adult worms as well as the individual worm burden in
each dog.

The field effectiveness study evaluates the effectiveness of the investigational new animal drug
under actual conditions of use in client-owned dogs and with the current enzootic status,
ecologic, and genetic factors affecting heartworm disease in dogs in each location.

FDA’s recommended approach considers the laboratory dose confirmation studies and the field
effectiveness study together when evaluating if substantial evidence of effectiveness (21 CFR
514.4) and inferential value to the target population have been met. FDA has provided certain
study design elements in the recommendations for the laboratory dose confirmation studies in
section **III. Laboratory Dose Confirmation Studies** (e.g., percent effectiveness threshold,
susceptibility characterization of isolates) based on the assumption that the conduct of the field
effectiveness study will incorporate the recommendations listed in section **IV. Field Effectiveness
Studies**.

### III. Laboratory Dose Confirmation Studies

The laboratory dose confirmation studies are intended to confirm effectiveness of the
investigational new animal drug under laboratory conditions. The studies should evaluate
effectiveness of a defined minimum labeled dose (mg/kg), dosage interval, and number of doses.
Timing of study procedures (infection, initiation of dosing) should be justified based on the
specific properties of the investigational new animal drug.

#### A. Number of Studies

FDA recommends sponsors conduct two induced laboratory dose confirmation studies,
each conducted at different laboratory facilities, led by different independent investigators,
and using recent isolates of *D. immitis* from two separate geographic locations in the
United States. For products applied topically, one of the two laboratory dose confirmation
studies should include evaluation of the effect of bathing and water immersion.

---

3 https://www.fda.gov/media/70333/download (May 2001)
4 For additional information about the recommended design and conduct of laboratory dose confirmation studies,
   refer to GFI #90 (VICH GL7) and GFI #111 (VICH GL19).
5 Locations which are sufficiently far enough apart that organisms isolated from those areas are likely to represent
distinct populations.
B. *D. immitis* Isolates

Laboratory dose confirmation studies should be conducted with *D. immitis* isolates that are established from current *D. immitis* populations circulating in the United States and that were established for experimental use within 5 years of study initiation. The two isolates should be from two separate geographic locations, and at least one of the two isolates should be from a highly endemic area, typically the southeastern United States\(^6\) or the Mississippi Delta Region.\(^7\) Isolates used in studies for investigational new animal drugs may, at the sponsor’s discretion, be characterized for susceptibility in accordance with the principles stated in GFI #90 (VICH GL7 regarding field isolate characterization prior to conduct of the laboratory dose confirmation studies.

C. Number of Dogs per Investigational Group

The chosen sample size should support the ethical principles of replacement, reduction, and refinement,\(^8\) and the goal of using the minimum number of animals necessary to generate data to demonstrate substantial evidence of effectiveness.

D. Number of L3 Injected for Induced Infection

FDA recommends that 50 infective *D. immitis* L3 larvae be injected subcutaneously per dog to introduce consistent and adequate infections without overburdening the negative control group dogs.

E. Pre-existing Heartworm Infection

FDA recommends testing for pre-existing (pre-study) heartworm infection at baseline and at approximately 120 days (4 months) after the day of experimental infection with *D. immitis* L3 larvae. Dogs determined to have pre-existing infections should be removed from the effectiveness evaluation.

F. Assessment of Effectiveness

1. Parasite Counts

The pivotal effectiveness variable is the *D. immitis* worm count (combined live and dead) at necropsy. Necropsy for *D. immitis* worm counts may occur as early as 150 days after infection with the *D. immitis* L3 larvae. Individuals conducting worm counts

---

\(^6\) FDA considers the southeastern United States to include the states of Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, South Carolina, and Tennessee.

\(^7\) FDA considers the Mississippi Delta Region to be the area covered by the Delta Regional Authority. Available online at [https://dra.gov/about-dra/map-room/] (Accessed February 20, 2024).

should have sufficient training and expertise to perform the counts and should be masked to treatment group.

Heartworm fragments, if any, should be counted as follows: Worm fragments containing a head and worm fragments containing a tail are counted separately. The greater of the two counts (number of fragments containing a head or number of fragments containing a tail) are included in the total worm count for effectiveness calculations. Fragments without heads or tails are not included in the worm count if fragments containing heads or tails are found. If only fragments without heads or tails are found, the fragments are collectively considered to represent one worm for inclusion in the effectiveness calculations.

2. Criteria to Demonstrate Effectiveness

In addition to having an adequate infection in the negative control group and a statistically significant difference in \( D. immitis \) worm count in the investigational new animal drug group compared to the negative control group, investigational new animal drugs should demonstrate at least 99.5 percent effectiveness and no more than one dog in the investigational new animal drug group should have one or more worms identified at necropsy. The geometric group means estimated from the statistical analysis of log-transformed worm counts should be used. Study design features (e.g., blocks, cohorts) should be included in the statistical model for the analysis.

\[
\text{Percent effectiveness} = \frac{(M_c - M_t)}{M_c} \times 100
\]

Where:

\( M_c \) = geometric mean back-transformed from the Least Squares mean of the control group, and

\( M_t \) = geometric mean back-transformed from the Least Squares mean of the investigational new animal drug group.

G. Pharmacokinetic Evaluation

FDA recommends the collection of pharmacokinetic data during the dose confirmation studies to verify dose exposure.

IV. Field Effectiveness Study

The field effectiveness study should be a multi-site study conducted with investigators in various geographic regions of the continental United States with endemic heartworm disease. FDA’s recommendations for specific study design elements are intended to increase the confidence that exposure to infective \( D. immitis \) larvae, as well as a variety of isolates, occurred during the evaluation period for the investigational new animal drug and that the evaluation of effectiveness is assessed appropriately.
A. Study Duration

Because of the length of the heartworm life cycle and the delay in the ability of diagnostic tests (heartworm antigen and microfilaria tests) to identify infection with adult heartworms after exposure to *D. immitis* larvae, the effectiveness of the investigational new animal drug is ultimately evaluated for only a portion of the total study duration (the effectiveness evaluation window).\(^9\)

FDA recommends that for products intended for monthly administration, the effectiveness evaluation window be a minimum of 6 months following the first dose. For products with a duration of effectiveness greater than 6 months, the effectiveness evaluation window should be the entire duration of effectiveness intended from one dose administration (for example, 12 months for a product to be administered every 12 months). The study should continue for an additional 240 days after the end of the effectiveness evaluation window to allow for the development and detection of adult heartworms (based on currently available testing methodologies) and collection of safety data (for example, a total study duration of at least 420 days for a product intended for monthly administration and at least 605 days for a product intended for yearly administration).

Longer study durations may be appropriate to address potential safety concerns identified during product development. Dogs should remain on the same drug product (either investigational new animal drug or active control) throughout the study.

B. Enrollment

The timing of enrollment should result in the investigational new animal drug being evaluated during the time of year that maximizes the likelihood of exposure to mosquitoes infected with *D. immitis*. In the Northern Hemisphere, peak transmission is considered to occur in July and August;\(^{10}\) therefore, unless the peak transmission season for a specific geographic location differs, the effectiveness evaluation window for studies conducted in the continental United States should include July and August. For example, in the case of an oral product intended for monthly administration,\(^{11}\) for all dogs to be treated with the investigational new animal drug, or active control, during the effectiveness evaluation window of July and August, the enrollment period for a field effectiveness study should be such that first dose administration occurs between April 1 and June 30.

---

\(^9\) The field safety of the investigational new animal drug is evaluated for the entire study.


\(^{11}\) In this example, the drug acts through the killing of larval stages with which the dog was infected within the prior 30 days.
C. Location of Study Sites

To evaluate the effectiveness of the investigational new animal drug in highly endemic portions of the United States, the majority (> 50 percent) of evaluable cases should be from the southeastern United States,\(^\text{12}\) eastern/central Oklahoma, eastern/central Texas, or the Mississippi Delta Region.\(^\text{13}\) No more than 40 percent of evaluable cases should be provided by one site.

D. Assessment of Effectiveness

Effectiveness and detection of pre-existing infection should be determined by commercial adult heartworm antigen testing and microfilaria detection testing by a concentration method (e.g., modified Knotts). FDA recommends that heartworm tests (antigen and microfilaria detection testing) be performed at baseline (prior to Day 0, the day of the first dose), at appropriate intervals to detect preexisting infection, and on the predetermined pivotal effectiveness study day based on the characteristics of the investigational new animal drug.

For an individual dog to be considered a success, the individual dog should not test heartworm antigen- or microfilaria-positive up to and including Day 120 (indicating a pre-existing infection), at any subsequent interim timepoints, and on the predetermined pivotal effectiveness day. Dogs testing positive between Day 120 and Day 240 should be evaluated on a case-by-case basis.

For an investigational new animal drug to be considered effective, the lower bound of the 95 percent two-sided confidence interval for the percent success for all evaluable cases in the investigational new animal drug group should be no lower than 98.0 percent. The confidence interval should be computed using exact methods for binomial proportions.\(^\text{14}\)

E. Active Control Group

To facilitate randomization and masking, and minimize bias in data collection,\(^\text{15}\) the study should include an active control group that is administered an FDA-approved product\(^\text{16}\) for

\[\text{footnote}\]
\[\text{footnote}\]
\[\text{footnote}\]
\[\text{footnote}\]
\[\text{footnote}\]
the prevention of heartworm disease in dogs. The ratio of cases allocated to the investigational new animal drug group to the active control group should be 1:1 or greater with a minimum of 50 control group animals. If possible, the active control should contain the same active ingredient and route of administration as the investigational new animal drug. The active control group is not used in the statistical evaluation of effectiveness.

F. Number of Evaluable Cases

The field effectiveness study should be large enough to provide independent substantiation of evidence and inferential value to the target population. The number of evaluable cases administered the investigational new animal drug should be at least 300 dogs. This number of minimum evaluable cases increases the confidence that exposure to \textit{D. immitis}-infected mosquitos occurred and that dogs were exposed to a variety of \textit{D. immitis} isolates during the study. In addition, sponsors should consider the proportion of likely treatment successes and the corresponding lower bound of the 95 percent confidence interval when considering the target sample size.

G. Pharmacokinetic Evaluation

FDA encourages the collection of pharmacokinetic data during the field effectiveness study to verify dose exposure.

\footnotetext{17 To avoid the unnecessary risk of developing heartworm disease in client-owned dogs, the study should not include a negative control group.}